Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

Ascend Biopharmaceuticals today announces that is has entered into an agreement with 3M Drug Delivery Systems to evaluate 3M’s Toll-Like Receptor 7/8 (TLR7/8) agonist 3M-051 in combination with Ascend’s proprietary cancer vaccine technology. The collaboration will support the creation and preclinical assessment of novel immunotherapy treatments to be potentially used for a number of different solid tumor types.

29 Nov 2013

New injectable therapy could help treat rotator cuff injuries

For a baseball pitcher, a rotator cuff injury often means an extended stay on the disabled list for surgery and rehabilitation of the damaged tendons. But a new technology under development may stop this shoulder injury from becoming so severe that surgery is required.

28 Nov 2013

Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer

Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer. However, the particles have to be injected into patients, which has limited their usefulness so far.

27 Nov 2013

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a phase 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus infection.

25 Nov 2013

Nano-material within cells could lead to engineered bio-composites for drug delivery, artificial tissue

New York-A team of researchers has uncovered critical information that could help scientists understand how protein polymers interact with other self-assembling biopolymers.

22 Nov 2013

Pharmaceutical powder characterisation and inhaler testing workshop to include expert presentations

A new workshop organised by Monash University will include invited presentations from Copley Scientific, the world’s leading provider of inhaler testing equipment, Freeman Technology, global leaders in the field of powder characterisation, and ATA Scientific, distributors of Malvern Panalytical materials characterisation systems.

From Malvern Panalytical 21 Nov 2013

Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases

Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, announces today it has signed a scientific collaboration agreement with Advanced Accelerator Applications, a fast growing international player in Molecular Nuclear Medicine. The financial terms of the deal have not been disclosed.

20 Nov 2013

Generex Biotechnology provides update on Phase II trial of AE37 breast cancer vaccine

Generex Biotechnology Corporation today announced that it has reached a pre-specified point in the ongoing Phase II trial of its AE37 breast cancer vaccine to initiate its primary efficacy analysis. The drug is a novel immunotherapeutic cancer vaccine being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. A previously released positive interim analysis showed a strong trend toward reduced relapse in breast cancer patients receiving the AE37 vaccine.

18 Nov 2013

Scientists join patients to address Friedreich's Ataxia

The Spanish Federation of Ataxia (FEDAES)—in representation of the GENEFA Platform for a Friedreich's Ataxia cure—, the Babel Family association for biomedical research into Friedreich's Ataxia, the "Centro de Biología Molecular Severo Ochoa" (CMBSO), and the Institute for Research in Biomedicine (IRB Barcelona) have signed an agreement through which these patients' associations will fund, by means of donations, a 3-year research project addressing Friedreich's Ataxia.

16 Nov 2013

New technique helps fight deadly pancreatic cancer using 2 types of nanoparticles

Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a new technique for fighting deadly and hard-to-treat pancreatic cancer that uses two different types of nanoparticles, the first type clearing a path into tumor cells for the second, which delivers chemotherapy drugs.

16 Nov 2013

New microbicide gel formulation shows promise for safe vaginal and rectal administration to prevent HIV

Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).

15 Nov 2013

Dual-wave nanotherapy method improves treatment of deadly pancreatic cancer

A new method of microscopic drug delivery that could greatly improve the treatment of deadly pancreatic cancer has been proven to work in mice at UCLA's Jonsson Comprehensive Cancer Center.

14 Nov 2013

Polymer for mending broken bones holds hope for delivering chemotherapy drugs to the brain

A polymer originally designed to help mend broken bones could be successful in delivering chemotherapy drugs directly to the brains of patients suffering from brain tumours, researchers at The University of Nottingham have discovered.

14 Nov 2013

International research consortium to focus on pediatric translational research

The Children's Hospital of Philadelphia CEO Steven M. Altschuler, Drexel University President John A. Fry, and Hebrew University of Jerusalem President Menahem Ben-Sasson signed a research agreement on November 11 as part of Philadelphia Mayor Michael A. Nutter's trade mission to Israel. The research partnership is designed to focus on pediatric translational research and to develop a collaborative platform for advancing pediatric medicine from the lab to the bedside.

13 Nov 2013

Scientists to develop on-demand drug-delivery system for pain management in osteoarthritis patients

Scientists are reporting development of a squishy gel that when compressed - like at a painful knee joint - releases anti-inflammatory medicine. The new material could someday deliver medications when and where osteoarthritis patients need it most. Their study appears in the ACS journal Biomacromolecules.

8 Nov 2013

SRI International awarded NIDA contract to study new treatment therapies for substance abuse

SRI International has been awarded a five-year contract valued up to $9.75 million from the National Institute on Drug Abuse to conduct preclinical safety studies of potential new medications to treat substance abuse. SRI researchers will study potential drug-drug interactions between new treatment therapies and common drugs of abuse to assess potential adverse reactions.

6 Nov 2013

Depomed reports financial results for third quarter 2013

Total revenues were $37.5 million and included recognition of a $5.0 million milestone payment from Mallinckrodt related to the NDA filing of MNK-795. Excluding this milestone and a $10 million upfront payment from Janssen in the third quarter of 2012, total revenues of $32.5 million grew 39% compared to $23.3 million for the third quarter of 2012.

6 Nov 2013

NTU establishes new $60 million research institute in Nanomedicine

Nanyang Technological University is giving the development of nanotechnology a big boost, by establishing a new $60 million research institute in Nanomedicine, which focuses on the medical application of nanotechnology. An emerging field in drugs, nanomedicine are made up of tiny nano-sized particles thousands of times smaller than a grain of sand.

5 Nov 2013

Cellectricon to demonstrate Cellaxess technology at Neuroscience 2013

Cellectricon, a leading provider of advanced cell-based screening technologies and services, will be presenting new data at Neuroscience 2013, 9-13 November, San Diego (USA).

From Cellectricon 31 Oct 2013

HDL-like particles could someday be used to combat atherosclerosis

A new type of "good cholesterol," made in the lab, could one day deliver drugs to where they are needed in the body to treat disease or be used in medical imaging, according to scientists.

30 Oct 2013

Drug Delivery News and Research

Further Reading

Ascend, 3M partner to develop and evaluate novel immunotherapy treatments for cancer

New injectable therapy could help treat rotator cuff injuries

Drugs delivered by nanoparticles hold promise for targeted treatment of many diseases, including cancer

Arrowhead seeks approval to start ARC-520 phase 2a trial for chronic hepatitis B infection

Nano-material within cells could lead to engineered bio-composites for drug delivery, artificial tissue

Pharmaceutical powder characterisation and inhaler testing workshop to include expert presentations

Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases

Generex Biotechnology provides update on Phase II trial of AE37 breast cancer vaccine

Scientists join patients to address Friedreich's Ataxia

New technique helps fight deadly pancreatic cancer using 2 types of nanoparticles

New microbicide gel formulation shows promise for safe vaginal and rectal administration to prevent HIV

Dual-wave nanotherapy method improves treatment of deadly pancreatic cancer

Polymer for mending broken bones holds hope for delivering chemotherapy drugs to the brain

International research consortium to focus on pediatric translational research

Scientists to develop on-demand drug-delivery system for pain management in osteoarthritis patients

SRI International awarded NIDA contract to study new treatment therapies for substance abuse

Depomed reports financial results for third quarter 2013

NTU establishes new $60 million research institute in Nanomedicine

Cellectricon to demonstrate Cellaxess technology at Neuroscience 2013

HDL-like particles could someday be used to combat atherosclerosis

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo